HIV

One-Sentence Definition

Human immunodeficiency virus (HIV-1/HIV-2) is an enveloped lentivirus (Retroviridae) that reverse-transcribes its RNA genome into DNA, integrates into host chromosomes, and progressively depletes CD4⁺ T cells, causing AIDS if untreated.

Taxonomy & Structure

  • HIV-1 (global pandemic) vs HIV-2 (West Africa, generally slower progression)
  • Dimeric (+)ssRNA; reverse transcriptase (RT), integrase, protease
  • Envelope gp120/gp41 (binds CD4 + CCR5/CXCR4 co-receptors)
  • Groups/subtypes (HIV-1 M subtypes A–K…) matter for diagnostics and epidemiology

Replication & Pathogenesis Highlights

  • Binding → fusion → RT → integration (provirus) → transcription/translation → assembly/budding
  • Latent reservoirs in resting CD4 cells — barrier to cure
  • Chronic immune activation; opportunistic infections and malignancies define AIDS
  • Transmission: blood, sexual, perinatal

Clinical Syndromes

  • Acute retroviral syndrome → chronic latency → AIDS (PJP, toxo, crypto, TB, KS, lymphoma…)
  • Non-AIDS comorbidities on long-term ART (CV, bone, neuro)

Diagnosis

  • Ag/Ab combo immunoassays → confirmatory differentiation; HIV RNA RT-PCR / qPCR for acute infection and infant diagnosis
  • Baseline: CD4 count, HIV RNA viral load, resistance genotype before/at ART failure
  • RNA Extraction for plasma viral load workflows

Treatment Notes (conceptual)

  • Combination ART (typically 2–3 active agents): NRTI/NNRTI/PI/INSTI classes — INSTI-based first-line common
  • Treat all; U=U (undetectable = untransmittable) when sustained suppression
  • PrEP / PEP for prevention; resistance testing guides switches
  • Opportunistic infection prophylaxis by CD4 thresholds

Antiviral Resistance

Genomics & Computational Notes

  • Pol sequencing for resistance; whole-genome / NGS for minority variants
  • Phylogenetics for transmission networks (ethical/privacy governance critical)
  • Phylodynamics of regional epidemics

Active Recall

  1. Why can’t ART currently cure HIV?
  2. Which assay detects infection before seroconversion?
  3. Name three antiretroviral drug-target classes.